Abstract
The role of thrombin in vascular pathology is a focus of investigation. The incorporation of direct factor-Xa inhibition into practice patterns is based on its theoretical dual-pathway attenuation of both thrombin generation and platelet aggregation. However, quantification of direct anti-Xa medications effect on platelet function is not established. Thromboelastography with Platelet Mapping (TEG-PM) leverages dual-pathway metrics to provide comprehensive coagulation profiles. We aimed to evaluate the effects of direct oral anticoagulants (DOACs) on coagulation and platelet function profiles and correlate these data with clinical endpoints including thrombosis in patients with PAD.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
